LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

Search

Catalyst Pharmaceuticals Inc

Cerrado

SectorSalud

23.67 -0.55

Resumen

Variación precio

24h

Actual

Mínimo

23.29

Máximo

23.98

Métricas clave

By Trading Economics

Ingresos

801K

57M

Ventas

-399K

141M

P/B

Media del Sector

18.191

56.602

BPA

0.68

Margen de beneficio

40.119

Empleados

181

EBITDA

526K

73M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+42.68% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-123M

2.9B

Apertura anterior

24.22

Cierre anterior

23.67

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

123 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Catalyst Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 may 2025, 23:20 UTC

Ganancias

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13 may 2025, 23:48 UTC

Charlas de Mercado

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13 may 2025, 23:43 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 may 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13 may 2025, 23:24 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

13 may 2025, 23:24 UTC

Charlas de Mercado
Ganancias

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13 may 2025, 22:58 UTC

Ganancias

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 may 2025, 22:58 UTC

Ganancias

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 may 2025, 22:58 UTC

Ganancias

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13 may 2025, 22:58 UTC

Ganancias

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13 may 2025, 22:38 UTC

Ganancias

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13 may 2025, 22:38 UTC

Ganancias

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13 may 2025, 22:37 UTC

Ganancias

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13 may 2025, 22:36 UTC

Ganancias

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13 may 2025, 22:35 UTC

Ganancias

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13 may 2025, 22:34 UTC

Ganancias

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13 may 2025, 22:33 UTC

Ganancias

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13 may 2025, 22:33 UTC

Ganancias

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13 may 2025, 22:33 UTC

Ganancias

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13 may 2025, 22:30 UTC

Ganancias

Aristocrat Interim Dividend 44 Australian Cents/Share

13 may 2025, 22:30 UTC

Ganancias

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13 may 2025, 22:29 UTC

Ganancias

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13 may 2025, 22:28 UTC

Ganancias

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13 may 2025, 21:15 UTC

Ganancias

Nu Holdings 1Q Rev $3.2B >NU

13 may 2025, 21:03 UTC

Principales Noticias

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13 may 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 may 2025, 20:32 UTC

Ganancias

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 may 2025, 20:31 UTC

Ganancias

Alcon 1Q Sales $2.45B >ALC.EB

13 may 2025, 20:30 UTC

Ganancias

Alcon 1Q Rev $2.47B >ALC.EB

13 may 2025, 20:30 UTC

Ganancias

Alcon 1Q EPS 70c >ALC.EB

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

42.68% repunte

Estimación a 12 meses

Media 34 USD  42.68%

Máximo 40 USD

Mínimo 31 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

123 / 382 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.